News
9d
MedPage Today on MSNWristband Nerve Stimulator Improves Essential Tremor OutcomesAt 90 days, participants randomized to the Felix NeuroAI transcutaneous peripheral nerve stimulation (TPNS) system showed ...
The Felix NeuroAI wristband delivers tailored and dynamic electrical stimulation to the ulnar, median, and radial nerves ...
Trump administration probing extent to which pharmaceutical imports may threaten national security, a likely prelude to ...
11d
MedPage Today on MSNComorbidities in Midlife Tied to Cancer RiskComorbidities in midlife were associated with a modestly higher risk of cancer overall and more strongly associated with a ...
McFarland placed the Idaho land for sale, the crown jewel of his operations, in December for $27 million. The property, which ...
The Trump administration carved out an exception for pharmaceuticals from the president's new tariff regime, at least for now ...
The global postpartum depression management market is projected to grow at a steady CAGR of 3.8% over the forecast period from 2022 to 2032. Valued at USD 115.1 million in 2022, the market is expected ...
Whether it is a question or an emergency, Poison Centers are there with life-saving information when you need it the most.
The constitutional position regarding exercise of powers by the President and the Governor is settled and clear. They have to ...
21d
MedPage Today on MSNSTRIDE: Semaglutide Shows it Has Legs in Peripheral Artery DiseaseSemaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building its positions in peripheral artery disease (PAD) and with an oral formulation, based ...
Hosted on MSN18d
Biotech Stock Roundup: SAGE, INCY Suffer Setbacks, JAZZ Wins Oncology Drug Approval & MoreSAGE will also discontinue the ongoing PURVIEW ... Dosing is expected to begin in the first quarter of 2025. Jazz Pharmaceuticals plc JAZZ announced that the FDA has granted accelerated approval ...
The FTSE 100 index closed down 352.90 points, 4.4%, at 7,702.08. The FTSE 250 ended 600.16 points lower, 3.3%, at 17,765.19. The AIM All-Share lost 16.12 points, 2.5%, at 624.42. The Cboe UK 100 ended ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results